Free Trial
NASDAQ:PDEX

Pro-Dex (PDEX) Stock Price, News & Analysis

Pro-Dex logo
$45.86 -21.44 (-31.86%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$46.42 +0.56 (+1.23%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pro-Dex Stock (NASDAQ:PDEX)

Key Stats

Today's Range
$42.40
$61.88
50-Day Range
$33.22
$69.00
52-Week Range
$16.84
$70.26
Volume
278,434 shs
Average Volume
27,319 shs
Market Capitalization
$149.55 million
P/E Ratio
22.82
Dividend Yield
N/A
Price Target
$52.00
Consensus Rating
Buy

Company Overview

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Pro-Dex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

PDEX MarketRank™: 

Pro-Dex scored higher than 48% of companies evaluated by MarketBeat, and ranked 789th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pro-Dex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pro-Dex has received no research coverage in the past 90 days.

  • Read more about Pro-Dex's stock forecast and price target.
  • Earnings Growth

    Earnings for Pro-Dex are expected to grow by 3.00% in the coming year, from $2.00 to $2.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pro-Dex is 22.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.01.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pro-Dex is 22.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.81.

  • Price to Book Value per Share Ratio

    Pro-Dex has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.82% of the float of Pro-Dex has been sold short.
  • Short Interest Ratio / Days to Cover

    Pro-Dex has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pro-Dex has recently increased by 61.90%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pro-Dex does not currently pay a dividend.

  • Dividend Growth

    Pro-Dex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.82% of the float of Pro-Dex has been sold short.
  • Short Interest Ratio / Days to Cover

    Pro-Dex has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pro-Dex has recently increased by 61.90%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pro-Dex has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Pro-Dex this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for PDEX on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Pro-Dex to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pro-Dex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,031,182.00 in company stock.

  • Percentage Held by Insiders

    47.50% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.28% of the stock of Pro-Dex is held by institutions.

  • Read more about Pro-Dex's insider trading history.
Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

PDEX Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Returns On Capital At Pro-Dex (NASDAQ:PDEX) Have Stalled
See More Headlines

PDEX Stock Analysis - Frequently Asked Questions

Pro-Dex's stock was trading at $46.75 on January 1st, 2025. Since then, PDEX shares have decreased by 1.9% and is now trading at $45.86.
View the best growth stocks for 2025 here
.

Pro-Dex, Inc. (NASDAQ:PDEX) released its earnings results on Thursday, May, 1st. The medical instruments supplier reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.51. The medical instruments supplier had revenue of $17.41 million for the quarter, compared to analyst estimates of $17.70 million. Pro-Dex had a trailing twelve-month return on equity of 21.68% and a net margin of 11.06%.

Top institutional shareholders of Pro-Dex include Ritholtz Wealth Management (0.49%) and Bank of New York Mellon Corp (0.20%). Insiders that own company stock include Alisha Charlton and Angelita Rebamontan Domingo.
View institutional ownership trends
.

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL).

Company Calendar

Last Earnings
5/01/2025
Today
5/05/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PDEX
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.00
High Stock Price Target
$52.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+13.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
22.82
Forward P/E Ratio
22.93
P/E Growth
N/A
Net Income
$2.13 million
Pretax Margin
14.34%

Debt

Sales & Book Value

Annual Sales
$61.00 million
Cash Flow
$1.32 per share
Price / Cash Flow
34.81
Book Value
$9.76 per share
Price / Book
4.70

Miscellaneous

Free Float
1,712,000
Market Cap
$149.55 million
Optionable
Not Optionable
Beta
0.37

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PDEX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners